In Vitro and in Vivo Evaluation of Ibuprofen Nanosuspensions for Enhanced Oral Bioavailability

Overview

Journal Med Princ Pract

Publisher Karger

Specialties General Medicine
Medical Education

Date 2021 Apr 6

PMID 33823524

Citations 2

Authors

Mohsen Hedaya

Farzana Bandarkar

Aly Nada

Affiliations

Soon will be listed here.

Abstract

Introduction: The objectives were to prepare, characterize, and evaluate different ibuprofen (IBU) nanosuspensions.

Methods: The nanosuspensions produced by ultrahomogenization were compared with a marketed IBU suspension for particle size, in vitro dissolution, and in vivo absorption. Five groups of rabbits were orally administered with 25 mg/kg of IBU nanosuspension, nanoparticles, unhomogenized suspension, marketed product, and untreated suspension. A sixth group received 5 mg/kg IBU intravenously. Blood samples obtained were analyzed by chromatography.

Results: The nanosuspensions showed significant decrease in particle size. Polyvinylpyrrolidone (PP) K30 profoundly increased aqueous solubility of IBU. Addition of Tween 80 (TW), in equal amount as PP (IBU:PP:TW, 1:2:2 w/w), resulted in much smaller particle size and better dissolution rate. The Cmax values achieved were 14.8 ± 1.64, 11.1 ± 1.37, 9.01 ± 0.761, 7.03 ± 1.38, and 3.23 ± 1.03 μg/mL, and the tmax values were 36 ± 8.2, 39 ± 8.2, 100 ± 17.3, 112 ± 15, and 105 ± 17 min for the nanosuspension, nanoparticle, unhomogenized suspension, marketed IBU suspension, and untreated IBU suspension in water, respectively. Bioavailability of the different formulations relative to the marketed suspension was found to be in the following sequence: nanosuspension > unhomogenized suspension > nanoparticles > untreated IBU suspension.

Conclusion: IBU/PP/TW nanosuspension showed enhanced in vitro and in vivo performance as compared to the marketed product. Nanosuspensions prepared by the ultrahigh-pressure homogenization technique can be used as a good formulation strategy to enhance the rate and extent of absorption of poorly soluble drugs.

Citing Articles

The Bioavailability of Drugs-The Current State of Knowledge.

Stielow M, Witczynska A, Kubryn N, Fijalkowski L, Nowaczyk J, Nowaczyk A Molecules. 2023; 28(24).

PMID: 38138529 PMC: 10745386. DOI: 10.3390/molecules28248038.

Do Polymeric Nanoparticles Really Enhance the Bioavailability of Oral Drugs? A Quantitative Answer Using Meta-Analysis.

Hathout R Gels. 2022; 8(2).

PMID: 35200500 PMC: 8872407. DOI: 10.3390/gels8020119.

References

Lai F, Sinico C, Ennas G, Marongiu F, Marongiu G, Fadda A . Diclofenac nanosuspensions: influence of preparation procedure and crystal form on drug dissolution behaviour. Int J Pharm. 2009; 373(1-2):124-32. DOI: 10.1016/j.ijpharm.2009.01.024. View

Friedrich H, Nada A, Bodmeier R . Solid state and dissolution rate characterization of co-ground mixtures of nifedipine and hydrophilic carriers. Drug Dev Ind Pharm. 2005; 31(8):719-28. DOI: 10.1080/03639040500216097. View

Kawabata Y, Wada K, Nakatani M, Yamada S, Onoue S . Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. Int J Pharm. 2011; 420(1):1-10. DOI: 10.1016/j.ijpharm.2011.08.032. View

Hussain M, Saxena V, Brausch J, Talukder R . Ibuprofen-phospholipid solid dispersions: improved dissolution and gastric tolerance. Int J Pharm. 2011; 422(1-2):290-4. DOI: 10.1016/j.ijpharm.2011.11.011. View

Leuner C, Dressman J . Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm. 2000; 50(1):47-60. DOI: 10.1016/s0939-6411(00)00076-x. View

Stella V, Nti-Addae K . Prodrug strategies to overcome poor water solubility. Adv Drug Deliv Rev. 2007; 59(7):677-94. DOI: 10.1016/j.addr.2007.05.013. View

Koh P, Chuah J, Talekar M, Gorajana A, Garg S . Formulation development and dissolution rate enhancement of efavirenz by solid dispersion systems. Indian J Pharm Sci. 2013; 75(3):291-301. PMC: 3783747. DOI: 10.4103/0250-474X.117434. View

Blagden N, De Matas M, Gavan P, York P . Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv Drug Deliv Rev. 2007; 59(7):617-30. DOI: 10.1016/j.addr.2007.05.011. View

Patel J, Patel R . Preparation, characterization and in vitro dissolution study of Nitrazepam: Cyclodextrin inclusion complex. J Pharm Bioallied Sci. 2012; 4(Suppl 1):S106-7. PMC: 3467855. DOI: 10.4103/0975-7406.94158. View

10.

Wang Y, Pi C, Feng X, Hou Y, Zhao L, Wei Y . The Influence of Nanoparticle Properties on Oral Bioavailability of Drugs. Int J Nanomedicine. 2020; 15:6295-6310. PMC: 7455773. DOI: 10.2147/IJN.S257269. View

11.

Hu L, Tang X, Cui F . Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs. J Pharm Pharmacol. 2004; 56(12):1527-35. DOI: 10.1211/0022357044959. View

12.

Jacobs C, Muller R . Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm Res. 2002; 19(2):189-94. DOI: 10.1023/a:1014276917363. View

13.

Peters K, Leitzke S, Diederichs J, Borner K, Hahn H, Muller R . Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J Antimicrob Chemother. 2000; 45(1):77-83. DOI: 10.1093/jac/45.1.77. View

14.

Wang Y, Li X, Wang L, Xu Y, Cheng X, Wei P . Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery. Int J Nanomedicine. 2011; 6:1497-507. PMC: 3141875. DOI: 10.2147/IJN.S21097. View

15.

Luo Y, Xiong X, Tian Y, Li Z, Gong Y, Li Y . A review of biodegradable polymeric systems for oral insulin delivery. Drug Deliv. 2015; 23(6):1882-91. DOI: 10.3109/10717544.2015.1052863. View

16.

Raman S, Polli J . Prediction of positive food effect: Bioavailability enhancement of BCS class II drugs. Int J Pharm. 2016; 506(1-2):110-5. DOI: 10.1016/j.ijpharm.2016.04.013. View

17.

Zhao Z, Hu Y, Hoerle R, Devine M, Raleigh M, Pentel P . A nanoparticle-based nicotine vaccine and the influence of particle size on its immunogenicity and efficacy. Nanomedicine. 2016; 13(2):443-454. PMC: 5298946. DOI: 10.1016/j.nano.2016.07.015. View

18.

Khattab I, Nada A, Zaghloul A . Physicochemical characterization of gliclazide-macrogol solid dispersion and tablets based on optimized dispersion. Drug Dev Ind Pharm. 2010; 36(8):893-902. DOI: 10.3109/03639040903578734. View

19.

Lee J, Choi J, Park C . Characteristics of polymers enabling nano-comminution of water-insoluble drugs. Int J Pharm. 2008; 355(1-2):328-36. DOI: 10.1016/j.ijpharm.2007.12.032. View

20.

Montero N, Alhajj M, Sierra M, Onate-Garzon J, Yarce C, Salamanca C . Development of Polyelectrolyte Complex Nanoparticles-PECNs Loaded with Ampicillin by Means of Polyelectrolyte Complexation and Ultra-High Pressure Homogenization (UHPH). Polymers (Basel). 2020; 12(5). PMC: 7285317. DOI: 10.3390/polym12051168. View